Total Dance Australia Blog

Would you like to become a Total Dance Australia guest contributor?  Do you have stories, handy hints & tips or an inspirational message you would love to share?

Submit your ideas to info@total-dance-aus.com along with your relevant details and background and we'll be in touch Xx 

Inspiring & Engaging the Dancers of Australia

 

Author: Teagan Lowe   Date Posted: 13 September 2021

Comment (3)

...

Author: Teagan Lowe   Date Posted: 11 May 2021

Comment (2)

Teaching Danc...

Author: Teagan Lowe   Date Posted: 26 March 2021

Comment (2)

...

Author: Teagan Lowe   Date Posted: 4 March 2021

Comment (2)

Work smart, not hard - how...

Author: Teagan Lowe   Date Posted: 25 February 2021

Comment (3)

Who is Teagan Lowe?...

Providing our readers with the skills and knowledge to support ...

Author: Leah Van Lambaart   Date Posted: 22 April 2020

Dancing Smarter Onlin...

Author: Leah Van Lambaart   Date Posted: 13 December 2019

Another year ...

Author: Leah Van Lambaart   Date Posted: 9 November 2019

...

Author: Leah Van Lambaart   Date Posted: 25 October 2019

How Eating A Rainbow Can I...

Author: Leah Van Lambaart   Date Posted: 31 August 2019

...

Author: Leah Van Lambaart   Date Posted: 2 August 2019

Becom...

Author: Leah Van Lambaart   Date Posted: 26 July 2019

Fuelling Your Energy...


Comments (1)

medication for the treatment of serious gram-posit

10 April 2022
oritavancin, sold under the brand name orbactiv, is a novel semisynthetic glycopeptide antibiotic medication for the treatment of serious gram-positive bacterial infections. its chemical structure as a lipoglycopeptide is similar to vancomycin. the u.s. food and drug administration (fda) and the european medicines agency (ema) have approved oritavancin for treatment of acute bacterial skin and skin structure infections. in vitro activity oritavancin shares certain properties with other members of the glycopeptide class of antibiotics, which includes vancomycin, the current standard of care for serious gram-positive infections in the united states and europe. it possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible gram-positive bacteria, including staphylococcus aureus, mrsa, enterococci, and streptococci. oritavancin was more active than either metronidazole or vancomycin against strains of clostridium difficile tested. oritavancin has potential use as a therapy for exposure to bacillus anthracis, the gram-positive bacterium that causes anthrax, having demonstrated efficacy in a mouse model both before and after exposure to the bacterium. mechanism the 4'-chlorobiphenylmethyl group disrupts the cell membrane of gram-positive bacteria. it also acts by inhibition of transglycosylation and inhibition of transpeptidation.

Leave a comment

Comments have to be approved before showing up